Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".
Burlington, MA, United States.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Flexion Therapeutics is implementing good security practices.
Read more about the latest issues in cybersecurity
An information security policy (ISP) is a set of rules, policies and procedures designed to ensure ...
According to the 2019 Cost of Data Breach Report from Ponemon Institute and IBM Security, the ...
Compare Flexion Therapeutics's security performance with other companies